DT-Web

DB00682 - Warfarin


Identification
Name Warfarin
Accession Number DB00682 (APRD00341)
Type small molecule
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral coagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 308.3279
Groups approved
Monoisotopic Weight 308.104859
Pharmacology
Indication For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.
Mechanism of action Warfarin inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.
Absorption Rapidly absorbed following oral administration with considerable interindividual variations. Also absorbed percutaneously.
Protein binding 99% bound primarily to albumin
Biotransformation Metabolized stereo- and regio-selectively by hepatic microsomal enzymes. S-warfarin is predominantly metabolized by cytochrome P450 (CYP) 2C9 to yield the 6- and 7-hydroxylated metabolites. R-warfarin is metabolized by CYP1A1, 1A2, and 3A4 to yield 6-, 8-, and 10-hydroxylated metabolites. Hydroxylated metabolites may be further conjugated prior to excretion into bile and urine. UGT1A1 appears to be responsible for producing the 6-O-glucuronide of warfarin, with a possibly contribution from UGT1A10. Five UGT1As may be involved in the formation of 7-O-glucuronide warfarin. S-warfarin has higher potency than R-warfarin and genetic polymorphisms in CYP2C9 may dramatically decrease clearance of and increase toxicity of the medication.
Route of elimination The elimination of warfarin is almost entirely by metabolism. Very little warfarin is excreted unchanged in urine. The metabolites are principally excreted into the urine; and to a lesser extent into the bile.
Toxicity LD50=374 (orally in mice)
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Acetaminophen Acetaminophen increases the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if acetaminophen is initiated, discontinued or dose changed.
Acetylsalicylic acid The antiplatelet effects of acetylsalicylic acid may increase the bleed risk associated with warfarin.
Allopurinol Allopurinol may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin times and therapeutic effects of warfarin if allopurinol is initiated, discontinued or dose changed.
Aminoglutethimide Aminoglutethimide may decrease the anticoagulant effect of warfarin by increasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if aminoglutethimide is initiated, discontinued or dose changed.
Aminosalicylic Acid The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin.
Amiodarone Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed.
Amobarbital Amobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if amobarbital is initiated, discontinued or dose changed.
Amprenavir Amprenavir may increase the anticoagulant effect of warfarin by increasing its serum concentration.
Aprepitant Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration.
Atazanavir The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin.
Avanafil Co-administration with avanafil resulted in an approximate 1.6% increase in AUC(0-inf) and 5.2% decrease in Cmax of S-warfarin.
Azathioprine Azathioprine may decrease the anticoagulant effect of warfarin.
Azithromycin Azithromycin may increase the anticoagulant effect of warfarin by increasing its serum concentration.
Betamethasone The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin.
Bezafibrate Bezafibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if bezafibrate is initiated, discontinued or dose changed.
Bosentan Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism.
Butabarbital Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed.
Butalbital Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed.
Capecitabine Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect.
Carbamazepine Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed.
Cefotetan The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin.
Cefoxitin The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin.
Ceftriaxone The cephalosporin, ceftriaxone, may increase the anticoagulant effect of warfarin.
Celecoxib Celecoxib may increase the anticoagulant effect of warfarin.
Cholestyramine The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of warfarin by decreasing its absorption.
Cimetidine Cimetidine may increase the serum concentration of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if cimetidine is initiated, discontinued or dose changed.
Ciprofloxacin The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin.
Cisapride Cisapride may increase the anticoagulant effect of warfarin.
Citalopram The SSRI, citalopram, increases the effect of anticoagulant, warfarin.
Clarithromycin The macrolide, clarithromycin, may increase the anticoagulant effect of warfarin.
Clofibrate The fibrate increases the anticoagulant effect
Clopidogrel Increased bleed risk may occur as a result of additive anticoagulant effects. Increase monitoring for signs and symptoms of bleeding during concomitant therapy.
Colestipol The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of warfarin by decreasing its absorption.
Cyclophosphamide The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of warfarin.
Danazol Danazol may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if danazol is initiated, discontinued or dose changed.
Delavirdine Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if delavirdine is initiated, discontinued or dose changed.
Demeclocycline The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin.
Desogestrel Desogestrol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if desogestrol is initiated, discontinued or dose changed.
Dexamethasone The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin.
Dextrothyroxine The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of warfarin.
Diclofenac The antiplatelet effects of oral diclofenac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Dicloxacillin Dicloxacillin may decrease the anticoagulant effect of warfarin.
Diflunisal The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Disulfiram Disulfiram may increase the anticoagulant effect of warfarin.
Doxycycline The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin.
Dronedarone Dronedarone is a moderate inhibitor of CYP3A4 which is responsible for warfarin metabolism. Increases serum concentration of S-isomer warfarin by 1.2 fold
Drospirenone Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed.
Drotrecogin alfa Increased risk of bleeding.
Erythromycin The macrolide, erythromycin, may increase the anticoagulant effect of warfarin.
Ethchlorvynol Ethchlorvynol may decrease the anticoagulant effect of warfarin.
Ethinyl Estradiol Ethinyl estradiol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethinyl estradiol is initiated, discontinued or dose changed.
Ethynodiol Diacetate Ethynodiol diacetate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethynodiol diacetate is initiated, discontinued or dose
Etodolac The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Etonogestrel Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed.
Etoricoxib Etoricoxib may increase the anticoagulant effect of warfarin.
Ezetimibe If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.
F decreases the effect of cortisone by metabolism alteration.
Fenofibrate Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed.
Fenoprofen The antiplatelet effects of fenoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Floxuridine Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if floxuridine is initiated, discontinued or dose changed.
Fluconazole Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed.
Fludrocortisone The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin.
Fluorouracil Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed.
Fluoxetine The SSRI, fluoxetine, increases the effect of anticoagulant, warfarin.
Fluoxymesterone Fluoxymesterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if fluoxymesterone is initiated, discontinued or dose changed.
Flurbiprofen Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed.
Fluvastatin Fluvastatin may increase the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if fluvastatin is initiated, discontinued or dose changed.
Fluvoxamine Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration.
Fosamprenavir The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of warfarin.
Fosphenytoin Increased hydantoin levels and risk of bleeding
Gadofosveset trisodium In a clinical trial of 10 patients receiving a stable dose of warfarin, a single dose of ABLAVAR (0.05 mmol/kg) did not alter the anticoagulant activity of warfarin as measured by the International Normalized Ratio (INR).
Gefitinib Gefitinib may increase the anticoagulant effect of warfarin.
Gemcitabine Gemcitabine may increase the anticoagulant effect of warfarin.
Gemfibrozil Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if gemfibrozil is initiated, discontinued or dose changed.
Ginkgo biloba Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
Ginseng Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
Glutethimide Glutethimide may decrease the serum concentration of warfarin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if glutethimide is initiated, discontinued or dose changed.
Griseofulvin Griseofulvin may decrease the anticoagulant effect of warfarin.
Homoharringtonine Avoid combination with warfarin and other anticoagulants due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL.
Hydrocortisone The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin.
Ibuprofen Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed.
Imatinib Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed.
Indinavir The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin.
Indomethacin Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed.
Isoniazid Isoniazid may increase the anticoagulant effect of warfarin.
Itraconazole Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism.
Ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.
Ketoprofen The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Ketorolac The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Leflunomide Leflunomide may increase the anticoagulant effect of warfarin.
Levamisole Levamisole may increase the anticoagulant effect of warfarin.
Levofloxacin The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin.
Levonorgestrel Levonorgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if levonorgestrel is initiated, discontinued or dose changed.
Levothyroxine Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed.
Liothyronine Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed.
Liotrix Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed.
Lomitapide Warfarin plasma concentrations may increase by lomitapide by 30%.. INR levels may increase by 22%. Regular INR monitoring is required.
Lovastatin Lovastatin may increase the anticoagulant effect warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if lovastatin is initiated, discontinued or dose changed .
Lumiracoxib Lumiracoxib may increase the anticoagulant effect of warfarin.
Meclofenamic acid The antiplatelet effects of meclofenamic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Medroxyprogesterone Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed.
Mefenamic acid Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed.
Mefloquine Mefloquine may increase the anticoagulant effect of warfarin.
Meloxicam The antiplatelet effects of meloxicam may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Mercaptopurine Mercaptopurine may decrease the anticoagulant effect of warfarin.
Mestranol Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed.
Methimazole Methimazole may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if methimazole is initiated, discontinued or dose changed.
Methohexital Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed.
Metronidazole Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed.
Miconazole Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if miconazole is initiated, discontinued or dose changed.
Minocycline The tetracycline, minocycline, may increase the anticoagulant effect of warfarin.
Mirabegron Mirabegron increased Cmax and AUC of S- and R-warfarin. Monitor concomitant therapy closely.
Mitotane Mitotane may decrease the anticoagulant effect of warfarin.
Moxifloxacin The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin.
Nabumetone The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Nafcillin Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed.
Nalidixic Acid The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin.
Nandrolone decanoate Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.
Nandrolone phenpropionate Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.
Naproxen The antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Nelfinavir The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin.
Nevirapine Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4.
Nicardipine Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed.
Norethindrone Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed.
Norfloxacin The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin.
Norgestimate Norgestimate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestimate is initiated, discontinued or dose changed.
Ofloxacin The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin.
Orlistat Orlistat may increase the anticoagulant effect of warfarin.
Oxandrolone Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed.
Oxaprozin The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
oxymetholone Oxymetholone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxymetholone is initiated, discontinued or dose changed.
Oxyphenbutazone The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin.
Paroxetine The SSRI, paroxetine, increases the effect of the anticoagulant, warfarin.
Pentobarbital Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed.
Pentoxifylline Pentoxifylline may increase the anticoagulant effect of warfarin.
Phenobarbital Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed.
Phenylbutazone The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin.
Phenytoin Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy.
Phytonadione Phytonadione (vitamin K) may antagonize the anticoagulant effects of warfarin. Monitor for changes in prothrombin time if phytonadione intake (either via supplements or vitamin K-rich foods) is increased or decreased.
Piroxicam Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed.
Prasugrel Coadministration with warfarin may increase the risk of bleeding.
Prednisolone The corticosteroid, prednisolone, alters the anticoagulant effect of warfarin.
Prednisone The corticosteroid, prednisone, alters the anticoagulant effect of warfarin.
Primidone The barbiturate, primidone, decreases the anticoagulant effect of warfarin.
Propafenone Propafenone may increase the anticoagulant effect of warfarin.
Propoxyphene Propoxyphene may increase the anticoagulant effect of warfarin.
Propylthiouracil Propylthiouracil may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if propylthiouracil is initiated, discontinued or dose changed.
Quinidine Quinidine may increase the anticoagulant effect of warfarin.
Quinine Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9.
Ranitidine Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence)
Rifabutin Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism.
Rifampin Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism.
S-Adenosylmethionine Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided.
Salicylate-sodium The antiplatelet effects of sodium salicylate may increase the bleed risk associated with warfarin.
Secobarbital Secobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if secobarbital is initiated, discontinued or dose changed.
Sitaxentan Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Warfarin doses should be decreased by 80% upon initiated of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of warfarin if sitaxentan is initiated, discontinued or dose changed.
St. John's Wort St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed.
Sucralfate Sucralfate may reduce the absorption of warfarin. Warfarin should be administered at least 2 hours before or 6 hours after sucralfate administration. Monitor for changes in prothrombin time if sucralfate is initiated, discontinued or dose changed.
Sulfadiazine Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed.
Sulfamethoxazole Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed.
Sulfinpyrazone Sulfinpyrazone may increase the anticoagulant effect of warfarin by decreasing its metabolism and protein binding.
Sulfisoxazole Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed.
Sulindac The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Tamoxifen Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk.
Telithromycin Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy.
Tenoxicam The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin.
Testolactone Testolactone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testolactone is initiated, discontinued or dose changed.
Testosterone Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed.
Testosterone Propionate The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.
Tetracycline Tetracycline may increase the anticoagulant effect of warfarin.
Thiopental Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed.
Tiaprofenic acid The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Ticlopidine Increased bleeding risk. Monitor INR.
Tigecycline Tigecycline may increase the serum concentration of warfarin.
Tolbutamide Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed.
Tolmetin The antiplatelet effects of tolmetin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
transdermal testosterone gel The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed.
Treprostinil The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy.
Triamcinolone The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin.
Triflusal The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of warfarin to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
Trimetrexate The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use.
Trisalicylate-choline The antiplatelet effects of trisalicylate-choline may increase the bleed risk associated with warfarin.
Vemurafenib Vemurafenib increases the AUC of S-warfarin (CYP2C9 substrate). Monitor concomitant therapy closely.
Vilazodone Increased risk of bleeding with concomitant use of warfarin and vilazodone.
Food Interactions
  • Avoid drastic changes in dietary habit.
  • Avoid St. John's Wort.
  • Consult your doctor before ingesting large amounts of dietary Vitamin K (e.g. from green leafy vegetables).
  • Avoid alcohol.
  • Limit garlic, ginger, gingko, and horse chestnut.

Targets


Vitamin K epoxide reductase complex subunit 1
Name Vitamin K epoxide reductase complex subunit 1
Gene Name VKORC1
Pharmacological action yes
Actions inhibitor
References
  • Gebauer M: Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem. 2007 Mar 15;15(6):2414-20. Epub 2007 Jan 17. - Pubmed
  • Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW: Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007 Jul;53(7):1199-205. Epub 2007 May 17. - Pubmed
  • Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007;120(1):1-10. Epub 2006 Dec 11. - Pubmed
  • Osman A, Enstrom C, Lindahl TL: Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype. Blood Coagul Fibrinolysis. 2007 Apr;18(3):293-6. - Pubmed
  • Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT: Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on Warfarin. Clin Pharmacol Ther. 2007 Jul 25;. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
DTHybrid score 0.5185

Enzymes


Cytochrome P450 2C9
Name Cytochrome P450 2C9
Gene Name CYP2C9
Actions substrate,inhibitor
References
  • Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. - Pubmed
  • Flockhart DA. - Drug Interactions: Cytochrome P450 Drug Interaction Table
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.6241
Cytochrome P450 1A2
Name Cytochrome P450 1A2
Gene Name CYP1A2
Actions substrate
References
  • Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. - Pubmed
  • Flockhart DA. - Drug Interactions: Cytochrome P450 Drug Interaction Table
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.5292
Cytochrome P450 2C19
Name Cytochrome P450 2C19
Gene Name CYP2C19
Actions substrate,inhibitor
References
  • Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. - Pubmed
  • Flockhart DA. - Drug Interactions: Cytochrome P450 Drug Interaction Table
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.5085
Cytochrome P450 3A4
Name Cytochrome P450 3A4
Gene Name CYP3A4
Actions substrate
References
  • Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. - Pubmed
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.7167
Cytochrome P450 2C8
Name Cytochrome P450 2C8
Gene Name CYP2C8
Actions substrate,inhibitor
References
  • Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. - Pubmed
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.4378
Cytochrome P450 2C18
Name Cytochrome P450 2C18
Gene Name CYP2C18
Actions substrate
References
  • Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. - Pubmed
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.2327
Cytochrome P450 1A1
Name Cytochrome P450 1A1
Gene Name CYP1A1
Actions substrate
References
  • Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. - Pubmed
DTHybrid score 0.2967

Carriers


Predictions


Id Partner name Gene Name Score
4119 Cytochrome P450 2D6 CYP2D6 0.3754
1588 Multidrug resistance protein 1 ABCB1 0.2968
4118 Cytochrome P450 3A5 CYP3A5 0.2414
6030 Cytochrome P450 2B6 CYP2B6 0.2159
6013 Cytochrome P450 2E1 CYP2E1 0.1919
6107 Cytochrome P450 3A7 CYP3A7 0.1717
5718 Cytochrome P450 2A6 CYP2A6 0.1422
20 Prostaglandin G/H synthase 1 PTGS1 0.1389
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.1194
1729 Solute carrier family 22 member 6 SLC22A6 0.085
290 Prostaglandin G/H synthase 2 PTGS2 0.0825
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0739
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0738
1898 Cytochrome P450 1B1 CYP1B1 0.0712
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0672
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0658
492 Histamine H1 receptor HRH1 0.0654
2159 Quinone oxidoreductase CRYZ 0.0653
824 Sodium-dependent serotonin transporter SLC6A4 0.0649
862 Multidrug resistance-associated protein 1 ABCC1 0.0612
6145 Solute carrier family 22 member 1 SLC22A1 0.0582
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0564
556 Alpha-1A adrenergic receptor ADRA1A 0.0556
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0552
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0547
502 5-hydroxytryptamine 2A receptor HTR2A 0.0509
2157 NAD(P)H dehydrogenase [quinone] 1 NQO1 0.0503
6144 Solute carrier family 22 member 2 SLC22A2 0.0496
3811 Cytochrome P450 19A1 CYP19A1 0.0493
320 5-hydroxytryptamine 1A receptor HTR1A 0.0477
6142 Solute carrier family 22 member 8 SLC22A8 0.0458
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0445
872 Gamma-aminobutyric-acid receptor subunit alpha-1 GABRA1 0.0438
831 D(2) dopamine receptor DRD2 0.0438
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0433
468 Cytochrome P450 4A11 CYP4A11 0.0423
136 Estrogen receptor ESR1 0.0412
2164 Multidrug resistance-associated protein 4 ABCC4 0.0406
318 Alpha-2A adrenergic receptor ADRA2A 0.0385
118 Organic cation/carnitine transporter 2 SLC22A5 0.0385
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0382
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0376
632 Alpha-1B adrenergic receptor ADRA1B 0.037
891 Dihydropteroate synthase folP 0.037
5359 Dihydropteroate synthase folP 0.037
7175 Dihydropteroate synthase sulI 0.037
23 D(1A) dopamine receptor DRD1 0.0367
776 Bile salt export pump ABCB11 0.0364
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.0364
766 Beta-2 adrenergic receptor ADRB2 0.0363
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0361
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0359
385 Potassium-transporting ATPase alpha chain 1 ATP4A 0.0352
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0347
789 Alpha-1D adrenergic receptor ADRA1D 0.034
193 Beta-1 adrenergic receptor ADRB1 0.0332
6143 Solute carrier family 22 member 7 SLC22A7 0.0327
36 Insulin receptor INSR 0.0325
844 Epidermal growth factor receptor EGFR 0.0317
3941 Amine oxidase [flavin-containing] A MAOA 0.0316
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0315
871 Glucocorticoid receptor NR3C1 0.0315
450 Muscarinic acetylcholine receptor M4 CHRM4 0.0307
465 Calmodulin CALM1 0.0306
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0303
590 5-hydroxytryptamine 2C receptor HTR2C 0.0299
847 Mu-type opioid receptor OPRM1 0.0297
1024 Solute carrier family 22 member 11 SLC22A11 0.0294
580 Gamma-aminobutyric-acid receptor subunit alpha-3 GABRA3 0.0293
230 ATP-binding cassette transporter sub-family C member 8 ABCC8 0.0293
423 Gamma-aminobutyric-acid receptor subunit alpha-2 GABRA2 0.0292
713 Sodium-dependent dopamine transporter SLC6A3 0.0289
731 HIV-1 protease HIV-1 protease 0.028
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0274
523 Gamma-aminobutyric-acid receptor subunit alpha-5 GABRA5 0.0273
6147 Solute carrier family 22 member 3 SLC22A3 0.0272
341 5-hydroxytryptamine 3 receptor HTR3A 0.027
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0267
260 Cytochrome P450 51 ERG11 0.0251
761 Cytochrome P450 51 ERG11 0.0251
3163 Cytochrome P450 51 cyp51 0.0251
238 Peroxisome proliferator-activated receptor gamma PPARG 0.025
696 Kappa-type opioid receptor OPRK1 0.0249
467 Delta-type opioid receptor OPRD1 0.0247
3939 Amine oxidase [flavin-containing] B MAOB 0.024
122 P2Y purinoceptor 12 P2RY12 0.0235
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0235
833 Organic cation/carnitine transporter 1 SLC22A4 0.0233
6031 Cytochrome P450 3A43 CYP3A43 0.0232
885 5-hydroxytryptamine 1B receptor HTR1B 0.0228
380 Cytochrome P450 17A1 CYP17A1 0.0225
4100 Gamma-aminobutyric-acid receptor subunit beta-2 GABRB2 0.0223
4099 Gamma-aminobutyric-acid receptor subunit beta-3 GABRB3 0.022
535 Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G 0.0218
4115 Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D 0.0216
817 DNA topoisomerase 2-alpha TOP2A 0.0216
1757 Myeloperoxidase MPO 0.0215
146 Androgen receptor AR 0.0212
3923 Cholinesterase BCHE 0.0211
478 Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C 0.0211
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.0209
6158 Solute carrier organic anion transporter family member 1C1 SLCO1C1 0.0209
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0206
777 Tumor necrosis factor TNF 0.0203
4111 Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 0.0202
1974 Oligopeptide transporter, kidney isoform SLC15A2 0.0201
1517 Beta-3 adrenergic receptor ADRB3 0.0199
70 Type-1 angiotensin II receptor AGTR1 0.0199
80 Peroxisome proliferator-activated receptor alpha PPARA 0.0198
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.0197
6014 Cytochrome P450 2A13 CYP2A13 0.0189
631 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 0.0189
3387 3-hydroxy-3-methylglutaryl-coenzyme A reductase mvaA 0.0189
6102 Arylamine N-acetyltransferase 2 NAT2 0.0183
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.0183
530 Gamma-aminobutyric-acid receptor subunit alpha-4 GABRA4 0.0182
629 Alpha-2B adrenergic receptor ADRA2B 0.0181
606 Cytochrome P450 27, mitochondrial CYP27A1 0.0178
400 Coagulation factor IX F9 0.0178
5461 Coagulation factor IX F9 0.0178
841 Gamma-aminobutyric-acid receptor subunit alpha-6 GABRA6 0.0177
6141 Sodium/bile acid cotransporter SLC10A1 0.0176
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.0176
725 5-hydroxytryptamine 1D receptor HTR1D 0.0174
4081 Vitamin K epoxide reductase complex subunit 1-like protein 1 VKORC1L1 0.0174
6177 UDP-glucuronosyltransferase 1-10 UGT1A10 0.0173
604 Vitamin K-dependent protein Z PROZ 0.0172
142 Gamma-aminobutyric-acid receptor subunit rho-1 GABRR1 0.0171
183 Vascular endothelial growth factor A VEGFA 0.017
2184 Cystic fibrosis transmembrane conductance regulator CFTR 0.017
4110 Voltage-dependent L-type calcium channel subunit beta-2 CACNB2 0.0169
1389 Transforming growth factor beta-1 TGFB1 0.0169
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.0167
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0164
638 D(3) dopamine receptor DRD3 0.0163
198 Sodium channel protein type 10 subunit alpha SCN10A 0.0163
6182 Cytochrome P450 2J2 CYP2J2 0.0163
756 Sex hormone-binding globulin SHBG 0.0163
477 DNA topoisomerase 4 subunit A parC 0.0162
886 DNA topoisomerase 4 subunit A parC 0.0162
6226 DNA topoisomerase 4 subunit A parC 0.0162
6093 Gamma-aminobutyric acid receptor subunit delta GABRD 0.0162
6089 Gamma-aminobutyric acid receptor subunit epsilon GABRE 0.0162
6087 Gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 0.0162
3947 Xanthine dehydrogenase/oxidase XDH 0.0162
373 Transthyretin TTR 0.0161
6020 Aldehyde oxidase AOX1 0.0161
15 Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I 0.016
404 DNA gyrase subunit A gyrA 0.016
6224 DNA gyrase subunit A gyrA 0.016
811 Translocator protein TSPO 0.0159
4098 Gamma-aminobutyric-acid receptor subunit beta-1 GABRB1 0.0157
85 Growth hormone receptor GHR 0.0156
6086 Gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 0.0156
6180 UDP-glucuronosyltransferase 2B4 UGT2B4 0.0155
378 Alpha-2C adrenergic receptor ADRA2C 0.0153
3804 Sodium channel protein type 4 subunit alpha SCN4A 0.0151
422 Vitamin K-dependent protein C PROC 0.0147
1245 Vitamin K-dependent protein S PROS1 0.0147
6148 Multidrug resistance-associated protein 7 ABCC10 0.0147
6088 Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 0.0146
6090 Gamma-aminobutyric acid receptor subunit pi GABRP 0.0146
6092 Gamma-aminobutyric acid receptor subunit rho-2 GABRR2 0.0146
6115 Gamma-aminobutyric acid receptor subunit rho-3 GABRR3 0.0146
6541 Peptostreptococcal albumin-binding protein pab 0.0142
485 cGMP-inhibited 3',5'-cyclic phosphodiesterase A PDE3A 0.0142
698 B-Raf proto-oncogene serine/threonine-protein kinase BRAF 0.0141
6220 Aryl hydrocarbon receptor AHR 0.0141
504 Mast/stem cell growth factor receptor KIT 0.0139
4604 Liver carboxylesterase 1 CES1 0.0137
614 Progesterone receptor PGR 0.0136
571 Melatonin receptor type 1A MTNR1A 0.0136
362 Melatonin receptor type 1B MTNR1B 0.0136
6136 Multidrug resistance-associated protein 5 ABCC5 0.0135
1050 Bile salt sulfotransferase SULT2A1 0.0133
3426 Glutamine synthetase glnA 0.0131
3987 Glutamine synthetase GLUL 0.0131
448 Vitamin K-dependent gamma-carboxylase GGCX 0.013
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.013
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.013
464 Glutamate [NMDA] receptor subunit epsilon-2 GRIN2B 0.0128
6085 Fatty acid-binding protein, intestinal FABP2 0.0127
204 cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A 0.0126
482 Glycine receptor subunit alpha-1 GLRA1 0.0126
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.0126
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.0126
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.0126
16 Adenosine A1 receptor ADORA1 0.0125
869 Estrogen receptor beta ESR2 0.0125
3917 Methylenetetrahydrofolate reductase MTHFR 0.0125
738 Monocarboxylate transporter 1 SLC16A1 0.0125
762 Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 0.0123
613 Atrial natriuretic peptide receptor A NPR1 0.0122
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0122
605 Fumarate reductase flavoprotein subunit frdA 0.0121
2709 Fumarate reductase flavoprotein subunit SO_0970 0.0121
3673 Fumarate reductase flavoprotein subunit fccA 0.0121
4912 Fumarate reductase flavoprotein subunit ifcA 0.0121
6549 Fumarate reductase flavoprotein subunit frdA 0.0121
1656 CYP2B protein CYP2B 0.0119
2183 Fatty acid-binding protein, adipocyte FABP4 0.0119
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0119
6432 Transporter snf 0.0118
239 Coagulation factor X F10 0.0117
6137 Multidrug resistance-associated protein 6 ABCC6 0.0116
432 D(4) dopamine receptor DRD4 0.0116
798 Osteocalcin BGLAP 0.0116
48 Pyridoxal kinase PDXK 0.0116
436 5-hydroxytryptamine 2B receptor HTR2B 0.0116
1010 Cytochrome P450 51A1 CYP51A1 0.0115
228 Beta platelet-derived growth factor receptor PDGFRB 0.0114
4113 Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F 0.0114
88 Retinoic acid receptor RXR-beta RXRB 0.0113
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0113
2499 Tubulin beta-2C chain TUBB2C 0.0113
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0113
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0113
1502 Peroxisome proliferator-activated receptor delta PPARD 0.0112
1178 Adenosine A2a receptor ADORA2A 0.0111
275 Arachidonate 5-lipoxygenase ALOX5 0.0111
3932 Glutathione S-transferase A2 GSTA2 0.0108
6174 50S ribosomal protein L32 rpmF 0.0108
2211 Fatty acid-binding protein, heart FABP3 0.0108
2449 Tubulin alpha-3 chain TUBA1A 0.0107
6091 Gamma-aminobutyric acid receptor subunit theta GABRQ 0.0107
6150 Solute carrier organic anion transporter family member 4C1 SLCO4C1 0.0107
124 Histamine H2 receptor HRH2 0.0106
6040 6-phosphogluconate dehydrogenase, decarboxylating PGD 0.0106
709 ATP-sensitive inward rectifier potassium channel 1 KCNJ1 0.0105
918 Glutamate receptor, ionotropic kainate 2 GRIK2 0.0104
147 Aldehyde dehydrogenase, mitochondrial ALDH2 0.0103
369 Coagulation factor VII F7 0.0103
818 50S ribosomal protein L10 rplJ 0.0102
837 Glutamate [NMDA] receptor subunit epsilon-1 GRIN2A 0.0101
780 Retinoic acid receptor RXR-gamma RXRG 0.0101
6169 ATP-binding cassette sub-family A member 5 ABCA5 0.01
407 Vascular endothelial growth factor receptor 2 KDR 0.01
17 Proto-oncogene tyrosine-protein kinase ABL1 ABL1 0.01
365 Dihydrofolate reductase DHFR 0.01
2381 Dihydrofolate reductase DFR1 0.01
2833 Dihydrofolate reductase Not Available 0.01
2931 Dihydrofolate reductase folA 0.01
3544 Dihydrofolate reductase folA 0.01
3682 Dihydrofolate reductase folA 0.01
6642 Dihydrofolate reductase folA 0.01
6756 Dihydrofolate reductase dfrA 0.01
54 Prothrombin F2 0.0099
592 Carbonic anhydrase 4 CA4 0.0099
6043 Putative G-protein coupled receptor 44 GPR44 0.0099
705 Glutamate receptor 1 GRIA1 0.0098
295 Carbonic anhydrase 1 CA1 0.0098
5787 Angiopoietin-1 receptor TEK 0.0098
4116 Dihydropteroate synthetase Not Available 0.0097
620 Bifunctional dihydrofolate reductase-thymidylate synthase Not Available 0.0097
958 Insulin-like growth factor 1 receptor IGF1R 0.0097
1618 High affinity nerve growth factor receptor NTRK1 0.0096
49 Endothelin B receptor EDNRB 0.0096
778 Cysteinyl leukotriene receptor 1 CYSLTR1 0.0095
921 Glutamate receptor 2 GRIA2 0.0095
558 Solute carrier family 12 member 1 SLC12A1 0.0094
566 Serotransferrin TF 0.0094
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.0094
716 5-hydroxytryptamine 7 receptor HTR7 0.0093
241 Calcium-transporting ATPase type 2C member 1 ATP2C1 0.0093
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0093
578 Endothelin-1 receptor EDNRA 0.009
26 Vascular endothelial growth factor receptor 3 FLT4 0.009
427 Substance-P receptor TACR1 0.0089
4120 NADPH--cytochrome P450 reductase POR 0.0089
621 Periplasmic [Fe] hydrogenase 1 Not Available 0.0088
768 FK506-binding protein 1A FKBP1A 0.0088
537 ATP synthase delta chain, mitochondrial ATP5D 0.0088
950 Alpha platelet-derived growth factor receptor PDGFRA 0.0088
4122 Histone deacetylase 2 HDAC2 0.0087
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.0087
162 Retinoic acid receptor gamma-1 RARG 0.0087
94 5-hydroxytryptamine 4 receptor HTR4 0.0086
32 Vascular endothelial growth factor receptor 1 FLT1 0.0086
3808 Dihydropteroate synthase 2 folP2 0.0085
4203 Histamine N-methyltransferase HNMT 0.0085
3601 Dihydropteroate synthase 1 folP1 0.0085
3807 Dihydropteroate synthase 1 folP1 0.0085
559 NADH-ubiquinone oxidoreductase chain 1 MT-ND1 0.0085
1457 Long-chain-fatty-acid--CoA ligase 4 ACSL4 0.0084
84 Nuclear receptor 0B1 NR0B1 0.0084
790 DNA polymerase subunit alpha B POLA2 0.0084
33 Cystine/glutamate transporter SLC7A11 0.0083
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0083
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0083
357 Carbonic anhydrase 2 CA2 0.0083
68 Cannabinoid receptor 1 CNR1 0.0083
2180 3-phosphoinositide-dependent protein kinase 1 PDPK1 0.0082
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0082
1787 Nuclear factor NF-kappa-B p105 subunit NFKB1 0.0082
29 Tubulin beta-1 chain TUBB1 0.0081
6045 Voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 0.0081
232 Corticosteroid-binding globulin SERPINA6 0.008
6525 Group IID secretory phospholipase A2 PLA2G2D 0.008
3802 Sodium channel protein type 2 subunit alpha SCN2A 0.008
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0079
645 Penicillin-binding protein 1A mrcA 0.0078
5805 Penicillin-binding protein 1A ponA 0.0078
6185 Penicillin-binding protein 1A mrcA 0.0078
6799 Penicillin-binding protein 1A pbpA 0.0078
442 Envelope glycoprotein gp41 0.0078
4859 Envelope glycoprotein env 0.0078
6153 Solute carrier organic anion transporter family member 4A1 SLCO4A1 0.0078
163 D(1B) dopamine receptor DRD5 0.0077
4177 Proto-oncogene tyrosine-protein kinase receptor ret RET 0.0077
541 cAMP-specific 3',5'-cyclic phosphodiesterase 4B PDE4B 0.0077
2038 Inhibitor of nuclear factor kappa-B kinase subunit beta IKBKB 0.0077
823 Fibroblast growth factor receptor 2 FGFR2 0.0076
806 Sodium/potassium-transporting ATPase alpha-1 chain ATP1A1 0.0075
4311 tRNA TRDMT1 0.0074
4325 tRNA trmD 0.0074
4328 tRNA trmD 0.0074
1541 Metalloproteinase mmp20 0.0074
1714 Mitogen-activated protein kinase 3 MAPK3 0.0074
4228 Keratin, type II cytoskeletal 7 KRT7 0.0074
543 Penicillin-binding protein 1B mrcB 0.0072
6186 Penicillin-binding protein 1B ponB 0.0072
6822 Penicillin-binding protein 1b pbp1b 0.0072
6844 Penicillin-binding protein 1b pbp1b 0.0072
820 Glycine receptor subunit alpha-2 GLRA2 0.0072
161 Tubulin beta chain TUBB 0.0072
312 Tubulin beta chain TUB2 0.0072
273 Apoptosis regulator Bcl-2 BCL2 0.0072
528 5-hydroxytryptamine 1E receptor HTR1E 0.0072
1 Peptidoglycan synthetase ftsI ftsI 0.0071
4155 Peptidoglycan synthetase ftsI ftsI 0.0071
814 Ryanodine receptor 1 RYR1 0.0071
1629 Transcription factor AP-1 JUN 0.0071
459 Retinoic acid receptor RXR-alpha RXRA 0.0071
24 Thymidylate synthase TMP1 0.0071
359 Thymidylate synthase TYMS 0.0071
2626 Thymidylate synthase thyA 0.0071
2729 Thymidylate synthase thyA 0.0071
5352 Thymidylate synthase THYA 0.0071
737 Mineralocorticoid receptor NR3C2 0.0071
6146 High affinity copper uptake protein 1 SLC31A1 0.0071
952 Dipeptidyl peptidase 4 DPP4 0.007
3810 Catechol O-methyltransferase COMT 0.007
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.007
1256 5-hydroxytryptamine 6 receptor HTR6 0.007
569 Retinal dehydrogenase 2 ALDH1A2 0.0069
1638 Solute carrier family 2, facilitated glucose transporter member 2 SLC2A2 0.0069
1992 Vitamin D-binding protein GC 0.0069
856 Vitamin D3 receptor VDR 0.0069
3937 Fatty-acid amide hydrolase FAAH 0.0068
2853 14 kDa fatty acid-binding protein Not Available 0.0068
515 26S proteasome non-ATPase regulatory subunit 1 PSMD1 0.0068
522 26S proteasome non-ATPase regulatory subunit 2 PSMD2 0.0068
439 Glutamate [NMDA] receptor subunit epsilon-4 GRIN2D 0.0068
518 Peroxidase/catalase T katG 0.0067
719 Retinoic acid receptor responder protein 1 RARRES1 0.0066
770 Retinoic acid-induced protein 3 GPRC5A 0.0066
139 Aldo-keto reductase family 1 member C1 AKR1C1 0.0066
2981 Phospholipase A2, membrane associated PLA2G2A 0.0066
567 Receptor tyrosine-protein kinase erbB-2 ERBB2 0.0066
611 Retinal dehydrogenase 1 ALDH1A1 0.0065
5934 Cytochrome P450 26A1 CYP26A1 0.0064
1820 Beta-nerve growth factor NGF 0.0064
6068 Guanylate cyclase soluble subunit alpha-2 GUCY1A2 0.0063
1648 Elastin ELN 0.0063
1192 Sulfotransferase 1A1 SULT1A1 0.0063
1119 Peroxiredoxin-5, mitochondrial PRDX5 0.0063
401 Glutamate [NMDA] receptor subunit zeta-1 GRIN1 0.0063
133 Dihydropterate synthase sulI 0.0063
581 Cytochrome P450 2R1 CYP2R1 0.0062
564 Cellular retinoic acid-binding protein 1 CRABP1 0.0062
1275 Estrogen sulfotransferase SULT1E1 0.0062
6126 Carbonic anhydrase 7 CA7 0.0062
634 Squalene monooxygenase SQLE 0.0062
7196 Squalene monooxygenase ERG1 0.0062
990 Dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 0.0062
4112 Voltage-dependent L-type calcium channel subunit beta-4 CACNB4 0.0061
4114 Voltage-dependent L-type calcium channel subunit beta-3 CACNB3 0.0061
505 Glutamate [NMDA] receptor subunit epsilon-3 GRIN2C 0.0061
474 Acetylcholinesterase ACHE 0.0061
284 DNA-directed RNA polymerase beta chain rpoB 0.006
5773 DNA-directed RNA polymerase beta chain rpoB 0.006
859 Cellular retinoic acid-binding protein 2 CRABP2 0.006
276 Sodium- and chloride-dependent GABA transporter 1 SLC6A1 0.006
6103 Arylamine N-acetyltransferase 1 NAT1 0.0059
633 Penicillin-binding proteins 1A/1B pbpA 0.0059
2222 Equilibrative nucleoside transporter 1 SLC29A1 0.0059
40 RAF proto-oncogene serine/threonine-protein kinase RAF1 0.0059
4148 Serine/threonine-protein kinase mTOR MTOR 0.0059
1360 Sphingomyelin phosphodiesterase SMPD1 0.0059
389 Amiloride-sensitive cation channel 2, neuronal ACCN2 0.0058
904 Glutathione S-transferase P GSTP1 0.0058
5880 Thrombopoietin receptor MPL 0.0058
6179 UDP-glucuronosyltransferase 2B17 UGT2B17 0.0058
6766 O-GlcNAcase BT_4395 BT_4395 0.0058
1971 cAMP-specific 3',5'-cyclic phosphodiesterase 4A PDE4A 0.0057
2539 Tubulin alpha-1 chain TUBA4A 0.0057
106 Cannabinoid receptor 2 CNR2 0.0057
4162 Potassium voltage-gated channel subfamily KQT member 3 KCNQ3 0.0056
333 Voltage-dependent L-type calcium channel subunit beta-1 CACNB1 0.0056
511 5-hydroxytryptamine 1F receptor HTR1F 0.0055
5300 Antigen peptide transporter 1 TAP1 0.0055
750 Voltage-dependent calcium channel gamma-1 subunit CACNG1 0.0054
976 Platelet glycoprotein IX GP9 0.0054
3970 Voltage-dependent N-type calcium channel subunit alpha-1B CACNA1B 0.0054
2112 Toll-like receptor 9 TLR9 0.0053
4103 Proteasome subunit beta type 2 PSMB2 0.0053
4102 Proteasome subunit beta type 5 PSMB5 0.0053
4101 Proteasome subunit beta type 1 PSMB1 0.0053
5998 Toll-like receptor 8 TLR8 0.0053
594 Thyroxine-binding globulin SERPINA7 0.0053
6038 Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6H 0.0052
6339 Ig kappa chain V-II region RPMI 6410 Not Available 0.0052
137 FolC bifunctional protein [Includes: Folylpolyglutamate synthase folC 0.0052
1864 RET proto-oncogene RET 0.0052
565 Extracellular calcium-sensing receptor CASR 0.0052
712 Tubulin alpha chain TUB1 0.0052
259 Microsomal triglyceride transfer protein large subunit MTTP 0.0052
1950 Epithelial discoidin domain-containing receptor 1 DDR1 0.0052
6170 ATP-binding cassette sub-family A member 3 ABCA3 0.0052
6094 BCR/ABL fusion protein isoform X9 BCR/ABL fusion 0.0052
6044 Serum paraoxonase/lactonase 3 PON3 0.0052
66 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II HSD3B2 0.0051
280 4-aminobutyrate aminotransferase, mitochondrial ABAT 0.0051
1039 Histone deacetylase 9 HDAC9 0.0051
6149 Solute carrier family 22 member 10 SLC22A10 0.0051
650 Aldo-keto reductase family 1 member C3 AKR1C3 0.005
229 Retinoic acid receptor beta RARB 0.005
751 Potassium channel subfamily K member 6 KCNK6 0.005
6027 Alkaline phosphatase, tissue-nonspecific isozyme ALPL 0.005
730 Retinoic acid receptor alpha RARA 0.0049
6037 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6G 0.0049
758 Thyroid hormone receptor alpha THRA 0.0049
6270 Group IIE secretory phospholipase A2 PLA2G2E 0.0048
6184 D-alanyl-D-alanine carboxypeptidase dacC dacC 0.0048
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.0048
3382 Glycolipid transfer protein GLTP 0.0046
172 Potassium channel subfamily K member 1 KCNK1 0.0046
173 Toll-like receptor 7 TLR7 0.0046
4237 50S ribosomal protein L22 rplV 0.0046
992 Protein tyrosine kinase 2 beta PTK2B 0.0045
527 Prostacyclin receptor PTGIR 0.0045
6206 DNA-directed RNA polymerase subunit beta' rpoC 0.0045
951 Macrophage colony-stimulating factor 1 receptor CSF1R 0.0045
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.0045
6100 BDNF/NT-3 growth factors receptor NTRK2 0.0044
115 Penicillin-binding protein 2 mrdA 0.0044
6069 Penicillin-binding protein 2 mrdA 0.0044
6118 Penicillin-binding protein 2 penA 0.0044
6187 Penicillin-binding protein 2 pbpA 0.0044
6686 Penicillin-binding protein 2 pbp2 0.0044
6939 Penicillin-binding protein 2 mrdA 0.0044
7163 Penicillin-binding protein 2 pbpA 0.0044
3809 Estrogen-related receptor gamma ESRRG 0.0044
208 DNA-directed RNA polymerase beta' chain rpoC 0.0044
5774 DNA-directed RNA polymerase beta' chain rpoC 0.0044
1196 Complement decay-accelerating factor CD55 0.0044
630 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial ACADSB 0.0044
182 2-oxoglutarate dehydrogenase E1 component, mitochondrial OGDH 0.0044
130 Prostacyclin synthase PTGIS 0.0044
2178 Metabotropic glutamate receptor 5 GRM5 0.0044
346 Thyroid hormone receptor beta-1 THRB 0.0044
5645 DNA topoisomerase 4 subunit B parE 0.0044
6227 DNA topoisomerase 4 subunit B parE 0.0044
887 DNA gyrase subunit B gyrB 0.0044
4150 DNA gyrase subunit B gyrB 0.0044
6225 DNA gyrase subunit B gyrB 0.0044
6033 High affinity interleukin-8 receptor A CXCR1 0.0044
3830 Calreticulin CALR 0.0043
3957 Adenosine deaminase ADA 0.0043
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0043
1483 Membrane copper amine oxidase AOC3 0.0043
3854 Basic fibroblast growth factor receptor 1 FGFR1 0.0043
461 Glycine receptor subunit alpha-3 GLRA3 0.0043
714 Glutathione reductase, mitochondrial GSR 0.0042
6155 ATP-binding cassette transporter sub-family C member 11 ABCC11 0.0042
1176 Mitogen-activated protein kinase 1 MAPK1 0.0041
424 Dihydroorotate dehydrogenase, mitochondrial DHODH 0.0041
6677 Myelin P2 protein PMP2 0.0041
6034 Hydroxyindole O-methyltransferase ASMT 0.0041
6035 Nuclear receptor ROR-beta RORB 0.0041
3997 Cytochrome P450 24A1, mitochondrial CYP24A1 0.0041
6036 Eosinophil peroxidase EPX 0.0041
469 Annexin A1 ANXA1 0.004
6046 Voltage-gated calcium channel beta 1 subunit splice variant CavB1d CACNB1 0.004
6032 PROBABLE FATTY ACID SYNTHASE FAS (FATTY ACID SYNTHETASE) fas 0.004
6508 Putative uncharacterized protein srtB 0.004
6543 Putative uncharacterized protein tcp14 0.004
6615 Putative uncharacterized protein MT0785 0.004
6623 Putative uncharacterized protein Not Available 0.004
6806 Putative uncharacterized protein AGR_C_2535 0.004
6813 Putative uncharacterized protein SAV4671 0.004
6815 Putative uncharacterized protein AFE_1514 0.004
6819 Putative uncharacterized protein RUMGNA_03254 0.004
6825 Putative uncharacterized protein CV_3270 0.004
4161 Furin FURIN 0.004
936 Ephrin type-A receptor 2 EPHA2 0.004
4217 Telomerase reverse transcriptase TERT 0.004
153 Dopamine beta-hydroxylase DBH 0.004
6154 Multidrug and toxin extrusion protein 1 SLC47A1 0.004
2236 Casein kinase II subunit alpha CSNK2A1 0.004
4210 Toll-like receptor 4 TLR4 0.0039
563 Thyroid peroxidase TPO 0.0039
6138 Multidrug resistance protein 3 ABCB4 0.0039
251 Alcohol dehydrogenase 1A ADH1A 0.0039
3639 Thymidine phosphorylase deoA 0.0039
3936 Thymidine phosphorylase TYMP 0.0039
4146 Phosphatidylinositol 3-kinase regulatory subunit gamma PIK3R3 0.0039
4145 Phosphatidylinositol 3-kinase regulatory subunit beta PIK3R2 0.0039
1129 C-C chemokine receptor type 5 CCR5 0.0039
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0039
6067 Penicillin binding protein 2a mecA 0.0038
2808 Chloramphenicol acetyltransferase 3 cat3 0.0038
368 Enoyl-[acyl-carrier-protein] reductase [NADH] inhA 0.0038
3228 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0038
3678 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0038
6856 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0038
170 Succinate semialdehyde dehydrogenase, mitochondrial ALDH5A1 0.0038
364 Corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 0.0038
268 Adenosine A2b receptor ADORA2B 0.0038
1302 Dihydropyrimidine dehydrogenase [NADP+] DPYD 0.0037
1291 cAMP response element-binding protein CREB1 0.0036
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.0036
199 Monocarboxylate transporter 8 SLC16A2 0.0036
4192 DNA topoisomerase 2-beta TOP2B 0.0036
819 Penicillin-binding protein 4 dacB 0.0036
765 Indoleamine 2,3-dioxygenase IDO1 0.0035
1374 Natriuretic peptides B NPPB 0.0035
5251 Carbonyl reductase [NADPH] 1 CBR1 0.0035
822 Aldose reductase AKR1B1 0.0035
4226 Uridine phosphorylase 2 UPP2 0.0035
185 Vasopressin V1a receptor AVPR1A 0.0035
1827 Gap junction alpha-1 protein GJA1 0.0035
1908 Vascular cell adhesion protein 1 VCAM1 0.0035
2417 Chloramphenicol acetyltransferase cat 0.0035
3278 Chloramphenicol acetyltransferase cat 0.0035
117 Sterol O-acyltransferase 1 SOAT1 0.0035
164 Histamine H4 receptor HRH4 0.0035
2810 Dr hemagglutinin structural subunit draA 0.0035
939 50S ribosomal protein L3 rplC 0.0035
165 FL cytokine receptor FLT3 0.0035
444 Alcohol dehydrogenase 1B ADH1B 0.0035
2718 Chloramphenicol 3-O phosphotransferase Not Available 0.0034
322 Vasopressin V2 receptor AVPR2 0.0034
267 Plasminogen activator inhibitor 1 SERPINE1 0.0034
908 Glutathione S-transferase theta-1 GSTT1 0.0034
6080 Neuronal acetylcholine receptor subunit alpha-5 CHRNA5 0.0033
6082 Neuronal acetylcholine receptor subunit beta-3 CHRNB3 0.0033
948 Neuronal acetylcholine receptor subunit beta-2 CHRNB2 0.0033
3856 Fibroblast growth factor receptor 3 FGFR3 0.0033
596 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 0.0033
1281 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 0.0033
4225 Uridine phosphorylase 1 UPP1 0.0033
7 Nitric oxide synthase, inducible NOS2 0.0032
331 Retinol-binding protein I, cellular RBP1 0.0032
65 Matrix metalloproteinase-9 Not Available 0.0032
1867 Major prion protein PRNP 0.0032
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0032
595 Fibrinogen alpha chain FGA 0.0032
140 30S ribosomal protein S9 rpsI 0.0031
6719 30S ribosomal protein S9 rpsI 0.0031
6725 30S ribosomal protein S9 rpsI 0.0031
2320 Thymidine kinase, cytosolic TK1 0.0031
3086 Plasmepsin-2 Not Available 0.0031
734 D1 dopamine receptor-interacting protein calcyon CALY 0.0031
1227 Cytochrome b MT-CYB 0.0031
6386 Cytochrome b petB 0.0031
6937 Cytochrome b MT-CYB 0.0031
674 Dihydroorotate dehydrogenase homolog, mitochondrial PFF0160c 0.0031
6081 Neuronal acetylcholine receptor subunit alpha-6 CHRNA6 0.0031
3760 Penicillin-binding protein 5 precursor dacA 0.0031
319 Opioid receptor, sigma 1 OPRS1 0.0031
6221 Steroid hormone receptor ERR1 ESRRA 0.0031
4097 Neuronal acetylcholine receptor subunit alpha-9 CHRNA9 0.0031
2578 Tubulin beta-3 chain TUBB3 0.003
413 Amidophosphoribosyltransferase PPAT 0.003
2515 Amidophosphoribosyltransferase purF 0.003
3714 Amidophosphoribosyltransferase purF 0.003
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.003
2285 Streptogramin A acetyltransferase vatD 0.003
2021 Thrombomodulin THBD 0.003
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.003
517 Alcohol dehydrogenase 1C ADH1C 0.003
245 Large neutral amino acids transporter small subunit 1 SLC7A5 0.0029
3813 Fibrinogen gamma chain FGG 0.0029
3812 Fibrinogen beta chain [Contains: Fibrinopeptide B] FGB 0.0029
4238 50S ribosomal protein L4 rplD 0.0029
5578 50S ribosomal protein L4 rplD 0.0029
6173 50S ribosomal protein L4 rplD 0.0029
6219 50S ribosomal protein L4 rplD 0.0029
1630 Integrin beta-2 ITGB2 0.0029
1569 G1/S-specific cyclin-D1 CCND1 0.0029
512 DNA-directed RNA polymerase alpha chain rpoA 0.0029
5772 DNA-directed RNA polymerase alpha chain rpoA 0.0029
2207 Rhodopsin RHO 0.0028
233 Potassium channel subfamily K member 2 KCNK2 0.0028
6123 Carbonic anhydrase 5A, mitochondrial CA5A 0.0028
6207 30S ribosomal protein S14 rpsN 0.0028
6209 30S ribosomal protein S19 rpsS 0.0028
6712 30S ribosomal protein S19 rpsS 0.0028
6726 30S ribosomal protein S19 rpsS 0.0028
935 Proto-oncogene tyrosine-protein kinase Yes YES1 0.0028
1063 Signal transducer and activator of transcription 5B STAT5B 0.0028
1525 Heparin-binding growth factor 2 FGF2 0.0028
5431 Lipid binding protein Not Available 0.0028
3616 Fatty acid-binding protein, epidermal FABP5 0.0028
5433 UPF0230 protein TM_1468 TM_1468 0.0028
6218 Pannexin-1 PANX1 0.0028
1278 Pro-epidermal growth factor EGF 0.0028
5430 Hepatocyte nuclear factor 4-gamma HNF4G 0.0028
1200 AMBP protein AMBP 0.0028
3866 Serum amyloid A protein SAA1 0.0028
1932 Apolipoprotein E APOE 0.0028
1852 Microtubule-associated protein 2 MAP2 0.0028
723 Cytosolic phospholipase A2 PLA2G4A 0.0027
215 Sodium channel protein type 11 subunit alpha SCN11A 0.0027
1144 Hepatocyte growth factor receptor MET 0.0027
4173 Tyrosine-protein kinase JAK2 JAK2 0.0027
102 DNA topoisomerase I, mitochondrial TOP1MT 0.0027
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0027
3849 Insulin-like growth factor-binding protein 7 IGFBP7 0.0027
2009 Protein NOV homolog NOV 0.0027
3847 Neuroendocrine convertase 2 PCSK2 0.0027
1949 Carboxypeptidase E CPE 0.0027
3850 Synaptotagmin-like protein 4 SYTL4 0.0027
3848 Neuroendocrine convertase 1 PCSK1 0.0027
3846 Retinoblastoma-associated protein RB1 0.0027
889 3-oxoacyl-[acyl-carrier-protein] synthase 1 fabB 0.0027
6860 3-oxoacyl-[acyl-carrier-protein] synthase 1 kasA 0.0027
5432 Trafficking protein particle complex subunit 3 TRAPPC3 0.0026
382 Glutamate receptor, ionotropic kainate 1 GRIK1 0.0026
174 Sigma 1-type opioid receptor SIGMAR1 0.0026
6131 Carbonic anhydrase 14 CA14 0.0026
896 Glutathione S-transferase Mu 1 GSTM1 0.0025
4252 Penicillin-binding protein 5 dacA 0.0025
3913 Glutamic acid decarboxylase GAD65 0.0025
390 Adenosine A3 receptor ADORA3 0.0025
937 Proto-oncogene tyrosine-protein kinase LCK LCK 0.0025
3961 G protein-activated inward rectifier potassium channel 4 KCNJ5 0.0025
934 Proto-oncogene tyrosine-protein kinase Fyn FYN 0.0024
544 Potassium voltage-gated channel subfamily E member 1 KCNE1 0.0024
159 Penicillin-binding protein 2B penA 0.0024
6121 Penicillin-binding protein 2B penA 0.0024
6039 Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A PDE11A 0.0024
6122 Carbonic anhydrase 3 CA3 0.0024
6231 Pepsin A PGA3 0.0024
6070 Nischarin NISCH 0.0024
5852 Type-2 angiotensin II receptor AGTR2 0.0024
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0024
642 3-oxo-5-alpha-steroid 4-dehydrogenase 2 SRD5A2 0.0023
489 Monocarboxylate transporter 2 SLC16A7 0.0023
283 SEC14-like protein 2 SEC14L2 0.0023
332 Beta-lactamase blaZ 0.0023
2478 Beta-lactamase ampC 0.0023
2613 Beta-lactamase ampC 0.0023
2635 Beta-lactamase ampC 0.0023
2700 Beta-lactamase penP 0.0023
5445 Beta-lactamase blaB 0.0023
6019 Beta-lactamase SHV-7 0.0023
6701 Beta-lactamase cphA 0.0023
550 Amiloride-sensitive sodium channel subunit delta SCNN1D 0.0023
27 Amiloride-sensitive sodium channel subunit beta SCNN1B 0.0023
552 Amiloride-sensitive sodium channel subunit gamma SCNN1G 0.0023
213 Amiloride-sensitive sodium channel subunit alpha SCNN1A 0.0023
1830 5'-nucleotidase NT5E 0.0023
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.0023
1353 DNA topoisomerase 1 TOP1 0.0023
3552 DNA topoisomerase 1 topA 0.0023
484 Tyrosine-protein kinase ABL2 ABL2 0.0022
476 RAC-alpha serine/threonine-protein kinase AKT1 0.0022
4209 ATP-sensitive inward rectifier potassium channel 8 KCNJ8 0.0022
6163 Copper-transporting ATPase 2 ATP7B 0.0022
6165 Copper-transporting ATPase 1 ATP7A 0.0022
6459 Glycodelin PAEP 0.0022
3610 Thioredoxin reductase 1, cytoplasmic TXNRD1 0.0022
572 Integrin alpha-L ITGAL 0.0022
3868 Calcineurin subunit B isoform 2 PPP3R2 0.0022
421 Calcium signal-modulating cyclophilin ligand CAMLG 0.0022
5798 Mitogen-activated protein kinase 11 MAPK11 0.0022
2155 Insulin-degrading enzyme IDE 0.0022
2232 Interleukin-5 IL5 0.0022
298 Renin REN 0.0021
1593 Mucin-2 MUC2 0.0021
6506 Stathmin-4 STMN4 0.0021
707 72 kDa type IV collagenase MMP2 0.0021
2091 Endoplasmin HSP90B1 0.0021
735 Alanine aminotransferase 1 GPT 0.0021
1244 Low-density lipoprotein receptor-related protein 2 LRP2 0.0021
3904 Alanine aminotransferase 2 GPT2 0.0021
521 ATP-binding cassette transporter sub-family C member 9 ABCC9 0.0021
741 Potassium voltage-gated channel subfamily KQT member 1 KCNQ1 0.0021
244 Angiotensin-converting enzyme ACE 0.0021
1792 Tissue-type plasminogen activator PLAT 0.0021
2450 Tyrosine-protein kinase ITK/TSK ITK 0.0021
828 Phenylalanine-4-hydroxylase PAH 0.0021
3109 Phenylalanine-4-hydroxylase phhA 0.0021
4152 Superoxide dismutase [Cu-Zn] SOD1 0.002
3090 Chitosanase csn 0.002
4149 Nuclear factor NF-kappa-B p100 subunit NFKB2 0.002
3611 Cytidine deaminase cdd 0.002
3707 Cytidine deaminase cdd 0.002
4211 Cytidine deaminase CDA 0.002
6501 Fatty acid-binding protein, liver FABP1 0.002
4199 Sphingosine 1-phosphate receptor Edg-8 S1PR5 0.002
796 Inosine-5'-monophosphate dehydrogenase 2 IMPDH2 0.002
838 Inosine-5'-monophosphate dehydrogenase 1 IMPDH1 0.002
6124 Carbonic anhydrase 5B, mitochondrial CA5B 0.0019
5923 Microtubule-associated protein tau MAPT 0.0019
5924 Microtubule-associated protein 4 MAP4 0.0019
132 ATP-binding cassette sub-family A member 1 ABCA1 0.0019
4948 Cytochrome c-553 Not Available 0.0019
4923 Cytochrome c3 DvMF_2499 0.0019
4945 Cytochrome c3 Not Available 0.0019
4949 Cytochrome c3 DVU_3171 0.0019
4968 Cytochrome c3 cytc3 0.0019
4997 Cytochrome c3 SO_2727 0.0019
5219 Cytochrome c3 cyd 0.0019
4902 Nine-heme cytochrome c Ddes_2038 0.0019
3189 High-molecular-weight cytochrome c hmcA 0.0019
6932 Calcium-activated potassium channel subunit beta-3 KCNMB3 0.0019
6931 Calcium-activated potassium channel subunit beta-1 KCNMB1 0.0019
6933 Calcium-activated potassium channel subunit beta-4 KCNMB4 0.0019
6934 Small conductance calcium-activated potassium channel protein 1 KCNN1 0.0019
6935 Small conductance calcium-activated potassium channel protein 2 KCNN2 0.0019
6936 Small conductance calcium-activated potassium channel protein 3 KCNN3 0.0019
1253 Interferon gamma IFNG 0.0018
6151 Monocarboxylate transporter 10 SLC16A10 0.0018
1262 Corticotropin-lipotropin POMC 0.0018
1968 ATP-sensitive inward rectifier potassium channel 12 KCNJ12 0.0018
6048 Troponin C, skeletal muscle TNNC2 0.0018
3312 Fatty acid-binding protein, brain FABP7 0.0018
683 Potassium transporter GK0582 0.0018
1198 Serum paraoxonase/arylesterase 1 PON1 0.0018
6223 Penicillin-binding protein 1C pbpC 0.0018
1123 Eosinophil cationic protein RNASE3 0.0018
67 Prolyl 4-hydroxylase subunit alpha-1 P4HA1 0.0017
4954 Soluble cytochrome b558 Not Available 0.0017
4934 Cytochrome c-551 nirM 0.0017
5218 Cytochrome c-551 nirM 0.0017
4943 Cytochrome c6 petJ 0.0017
4905 Cytochrome c2 Not Available 0.0017
4939 Cytochrome c2 cycA 0.0017
4964 Cytochrome c2 cycA 0.0017
4979 Cytochrome c2 cycA 0.0017
6673 Cytochrome c2 cycA 0.0017
4947 Bacterial hemoglobin vhb 0.0017
4915 Cytochrome c-550 psbV 0.0017
4959 Cytochrome c-550 psbV 0.0017
5216 Cytochrome c-550 psbV 0.0017
4925 Cytochrome c-type protein SHP shp 0.0017
4975 Cytochrome c-556 RPA3973 0.0017
4916 Cyanoglobin glbN 0.0017
4998 Hemoglobin-like protein yjbI yjbI 0.0017
4984 Neuroglobin NGB 0.0017
3116 Bacterioferritin bfr 0.0017
4906 Bacterioferritin bfr 0.0017
4965 Bacterioferritin bfr 0.0017
4936 Cytochrome c2 iso-2 Not Available 0.0017
4994 Hemoglobin-like protein HbO glbO 0.0017
4942 Diheme cytochrome c napB napB 0.0017
4909 CooA protein cooA 0.0017
4907 Cytochrome c-L moxG 0.0017
6865 Cytochrome c-L moxG 0.0017
5000 HemO hemO 0.0017
4935 Cytochrome c-554 cycA1 0.0017
644 Heme oxygenase 2 HMOX2 0.0017
4982 Heme oxygenase 2 pbsA2 0.0017
4981 Iron-starvation protein PigA pigA 0.0017
4961 Hemophore HasA hasA 0.0017
4910 Cytoglobin CYGB 0.0017
4904 Cytochrome c family protein GSU1996 0.0017
4971 Nonaheme cytochrome c hmcA 0.0017
4989 Cytochrome c551 peroxidase ccp 0.0017
5222 Cytochrome c551 peroxidase ccpA 0.0017
4976 Apocytochrome f petA 0.0017
6407 Apocytochrome f petA 0.0017
4931 Cytochrome P450 167A1 CYP167A1 0.0017
4999 Cytochrome P450 165B3 CYP165B3 0.0017
4764 Cytochrome P450 165C4 CYP165C4 0.0017
4960 Putative cytochrome P450-family protein SCO7417 0.0017
4937 Cytochrome oxidase subunit II rcoxA 0.0017
4926 Heme-based aerotactic transducer hemAT hemAT 0.0017
4903 Methyl-accepting chemotaxis protein Tar4 0.0017
4993 Hydroxylamine oxidoreductase hao1 0.0017
4922 Cytochrome c, putative SO_4144 0.0017
4972 P450cin cinA 0.0017
4970 Cytochrome c nitrite reductase catalytic subunit nrfA 0.0017
4952 Catalase/peroxidase katA 0.0017
3093 Catalase HPII katE 0.0017
4908 Heme-regulated cyclic AMP phosphodiesterase dosP 0.0017
591 Glutamate [NMDA] receptor subunit 3B GRIN3B 0.0017
1524 Peptidyl-prolyl cis-trans isomerase A PPIA 0.0017
6700 Peptidyl-prolyl cis-trans isomerase A ppiA 0.0017
5878 Alpha-7 nicotinic cholinergic receptor subunit CHRFAM7A 0.0017
6824 Tyrosine-protein kinase Lyn LYN 0.0017
4773 Deoxycytidine kinase DCK 0.0017
6042 Prostaglandin reductase 2 PTGR2 0.0016
5463 Calcium-activated potassium channel subunit beta 2 KCNMB2 0.0016
1768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit GNG2 0.0016
1268 Neuropeptide S receptor NPSR1 0.0016
1571 G protein-activated inward rectifier potassium channel 1 KCNJ3 0.0016
1581 G protein-activated inward rectifier potassium channel 2 KCNJ6 0.0016
291 Nitric-oxide synthase, endothelial NOS3 0.0016
4386 Hemoglobin-like protein HbN glbN 0.0016
1243 Cathepsin D CTSD 0.0016
3007 Carbonic anhydrase 12 CA12 0.0016
4205 Carbonic anhydrase 9 CA9 0.0016
3233 Bile acid receptor NR1H4 0.0015
6140 Ileal sodium/bile acid cotransporter SLC10A2 0.0015
3844 HLA class II histocompatibility antigen, DQ(6) alpha chain HLA-DQA2 0.0015
1939 Heat shock protein HSP 90-alpha HSP90AA1 0.0015
760 Fibroblast growth factor 1 FGF1 0.0015
6073 Potassium channel subfamily K member 9 KCNK9 0.0015
6072 Potassium channel subfamily K member 3 KCNK3 0.0015
3221 Cytochrome c4 cc4 0.0014
1341 Histamine H3 receptor HRH3 0.0014
6167 Organic solute transporter subunit beta OSTB 0.0014
6166 Organic solute transporter subunit alpha OSTA 0.0014
2599 Tyrosine-protein kinase HCK HCK 0.0014
6859 Protein S100-A4 S100A4 0.0014
2300 Lysozyme E 0.0014
3633 Lysozyme R 0.0014
5597 Lysozyme 17 0.0014
6160 Solute carrier organic anion transporter family member 3A1 SLCO3A1 0.0014
2298 Cytochrome P450-cam camC 0.0013
2216 Fibroblast growth factor receptor 4 FGFR4 0.0013
561 Retinol-binding protein II, cellular RBP2 0.0013
35 Dehydrogenase/reductase SDR family member 4 DHRS4 0.0013
4073 Retinol dehydrogenase 11 RDH11 0.0013
4074 Retinol dehydrogenase 14 RDH14 0.0013
1097 Lecithin retinol acyltransferase LRAT 0.0013
589 Retinoid-binding protein 7 RBP7 0.0013
753 Retinol-binding protein III, cellular RBP5 0.0013
4071 Short-chain dehydrogenase/reductase 3 DHRS3 0.0013
4075 Photoreceptor outer segment all-trans retinol dehydrogenase RDH8 0.0013
863 Cellular retinaldehyde-binding protein RLBP1 0.0013
800 Retinol dehydrogenase 12 RDH12 0.0013
282 Interphotoreceptor retinoid-binding protein RBP3 0.0013
651 Retinol dehydrogenase 13 RDH13 0.0013
4072 All-trans-retinol 13,14-reductase RETSAT 0.0013
4920 Peroxidase/catalase katG 0.0013
2119 Cytochrome b5 CYB5A 0.0013
4956 Quinohemoprotein alcohol dehydrogenase ADH IIB qbdA 0.0013
4990 PpcA ppcA 0.0013
4988 Sulfite oxidase, mitochondrial SUOX 0.0013
3375 Acidic cytochrome c3 Not Available 0.0013
4037 Hypothetical protein GPX1 0.0013
4297 Hypothetical protein SP_1951 0.0013
4521 Hypothetical protein BC_2969 0.0013
4540 Hypothetical protein TM_1070 0.0013
4555 Hypothetical protein MT1739 0.0013
4569 Hypothetical protein mshD 0.0013
4578 Hypothetical protein PA3270 0.0013
4747 Hypothetical protein PA3967 0.0013
5177 Hypothetical protein TM_0096 0.0013
5194 Hypothetical protein PA1204 0.0013
5240 Hypothetical protein Rv2991 0.0013
5370 Hypothetical protein TM_1158 0.0013
5710 Hypothetical protein Tb927.5.1360 0.0013
4385 Cytochrome c' Not Available 0.0013
4967 Cytochrome c' cycA 0.0013
5038 Cytochrome c' Not Available 0.0013
5223 Cytochrome c' cycP 0.0013
3570 Cytochrome P450 152A1 cypC 0.0013
2915 Sensor protein fixL fixL 0.0013
4944 Sensor protein fixL fixL 0.0013
1313 Lactoylglutathione lyase GLO1 0.0013
4992 Cytochrome c peroxidase Not Available 0.0013
5626 Nucleoside diphosphate kinase B NME2 0.0013
4289 Cytochrome P450 TT_P0059 0.0013
6262 Cytochrome P450 staP 0.0013
4813 Heme oxygenase hmuO 0.0013
5769 Heme oxygenase Not Available 0.0013
1405 Thiopurine S-methyltransferase TPMT 0.0013
6116 Gastric triacylglycerol lipase LIPF 0.0012
1507 Cytochrome c CYCS 0.0012
2230 Catalase CAT 0.0012
3249 Catalase katA 0.0012
3625 Catalase katA 0.0012
4539 Catalase katA 0.0012
4941 Catalase katB 0.0012
3806 cGMP-dependent 3',5'-cyclic phosphodiesterase PDE2A 0.0012
3823 Cytokine receptor common gamma chain IL2RG 0.0012
2107 Microtubule-associated protein 1A MAP1A 0.0012
338 DNA polymerase UL30 0.0012
379 DNA polymerase UL54 0.0012
697 DNA polymerase ORF28 0.0012
2482 DNA polymerase 43 0.0012
4104 DNA polymerase BALF5 0.0012
997 Protein kinase C beta type PRKCB 0.0012
200 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 0.0012
451 Carnitine O-palmitoyltransferase I, liver isoform CPT1A 0.0012
1295 Fatty acid synthase FASN 0.0012
627 11-cis retinol dehydrogenase RDH5 0.0011
640 Aldehyde dehydrogenase 1A3 ALDH1A3 0.0011
1970 Protein kinase C alpha type PRKCA 0.0011
754 Pancreatic triacylglycerol lipase PNLIP 0.0011
3670 Soluble cytochrome b562 precursor cybC 0.0011
3411 Cytochrome P450 121 cyp121 0.0011
3291 Cytochrome c-552 cycA 0.0011
4927 Cytochrome c-552 nrfA 0.0011
4938 Cytochrome c-552 cycA 0.0011
4953 Cytochrome c-552 nrfA 0.0011
5217 Cytochrome c-552 cycM 0.0011
2617 Nitric oxide synthase oxygenase nos 0.0011
2701 Nitric oxide synthase oxygenase nos 0.0011
3102 Flavohemoprotein hmp 0.0011
4969 Flavohemoprotein hmp 0.0011
2408 Tyrosine-protein kinase SYK SYK 0.0011
724 Interleukin-2 receptor alpha chain IL2RA 0.0011
717 Interleukin-2 receptor subunit beta IL2RB 0.0011
1810 Protein S100-A1 S100A1 0.001
6097 Protein S100-A2 S100A2 0.001
2461 D-alanyl-D-alanine carboxypeptidase Not Available 0.001
5756 D-alanyl-D-alanine carboxypeptidase dac 0.001
493 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial CYP27B1 0.001
5294 Nucleoside diphosphate kinase A NME1 0.001
695 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A PDE10A 0.001
345 Plasma retinol-binding protein RBP4 0.001
4041 Microsomal glutathione S-transferase 2 MGST2 0.001
2845 Bifunctional P-450:NADPH-P450 reductase CYP102A1 0.001
2972 6-deoxyerythronolide B hydroxylase eryF 0.001
6228 Nuclear receptor coactivator 1 NCOA1 0.001
6263 cAMP-dependent protein kinase catalytic subunit alpha PRKACA 0.001
6837 Serine/threonine-protein kinase 17B STK17B 0.001
6836 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial HIBCH 0.001
2268 Cholesterol oxidase choB 0.0009
2822 Cholesterol oxidase choA 0.0009
4608 Putative cytochrome P450 SCO1207 0.0009
4963 Putative cytochrome P450 SCO2884 0.0009
6254 Putative cytochrome P450 SCO6998 0.0009
6105 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 0.0009
1048 Protein S100-A13 S100A13 0.0009
2226 Protein S100-A12 S100A12 0.0009
1759 85 kDa calcium-independent phospholipase A2 PLA2G6 0.0009
1770 Phospholipase C PLCL1 0.0009
2841 Phospholipase C plc 0.0009
358 Cystathionine beta-synthase CBS 0.0009
2283 Steroid Delta-isomerase ksi 0.0009
2920 Steroid Delta-isomerase ksi 0.0009
2132 Protein S100-B S100B 0.0009
3404 Exotoxin A eta 0.0008
6656 UDP-glucuronosyltransferase 3A1 UGT3A1 0.0008
22 30S ribosomal protein S4 rpsD 0.0008
6714 30S ribosomal protein S4 rpsD 0.0008
693 Hemoglobin subunit beta HBB 0.0008
2325 Sulfotransferase family cytosolic 2B member 1 SULT2B1 0.0008
6268 Hydroxyacid oxidase 1 HAO1 0.0008
4031 Glutathione S-transferase A1 GSTA1 0.0008
6599 HTH-type transcriptional regulator ttgR ttgR 0.0008
76 Nitric-oxide synthase, brain NOS1 0.0008
1649 Small inducible cytokine A2 CCL2 0.0008
810 Heme oxygenase 1 HMOX1 0.0008
3391 Heme oxygenase 1 pbsA1 0.0008
1025 Aquaporin-1 AQP1 0.0008
5766 NAD-dependent deacetylase sirtuin-5 SIRT5 0.0008
6893 Calcium/calmodulin-dependent protein kinase type II gamma chain CAMK2G 0.0007
473 L-lactate dehydrogenase A chain LDHA 0.0007
217 Estradiol 17-beta-dehydrogenase 1 HSD17B1 0.0007
5818 Folate receptor alpha FOLR1 0.0007
6344 ATP synthase subunit gamma, mitochondrial ATP5C1 0.0007
6343 ATP synthase subunit beta, mitochondrial ATP5B 0.0007
6342 ATP synthase subunit alpha, mitochondrial ATP5A1 0.0007
6134 Sodium channel subunit beta-3 SCN3B 0.0007
6133 Sodium channel subunit beta-2 SCN2B 0.0007
6135 Sodium channel subunit beta-4 SCN4B 0.0007
6241 Nuclear receptor coactivator 2 NCOA2 0.0007
6132 Sodium channel subunit beta-1 SCN1B 0.0007
6129 Carbonic anhydrase-related protein 11 CA11 0.0007
6127 Carbonic anhydrase-related protein CA8 0.0007
6128 Carbonic anhydrase-related protein 10 CA10 0.0007
2290 ADP-ribosyl cyclase 2 BST1 0.0007
226 Gonadotropin-releasing hormone receptor GNRHR 0.0007
125 DNA polymerase beta POLB 0.0007
131 Synaptic vesicular amine transporter SLC18A2 0.0007
144 Hemoglobin subunit alpha HBA1 0.0006
293 Gamma-glutamyl hydrolase GGH 0.0006
3803 Sodium channel protein type 3 subunit alpha SCN3A 0.0006
6259 (3R)-hydroxymyristoyl-acyl carrier protein dehydratase fabZ 0.0006
6130 Carbonic anhydrase 13 CA13 0.0006
890 Niemann-Pick C1-like protein 1 NPC1L1 0.0006
3126 Poly [ADP-ribose] polymerase 1 PARP1 0.0006
2404 Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform PIK3CG 0.0006
1650 Heme carrier protein 1 SLC46A1 0.0006
773 Folylpolyglutamate synthase, mitochondrial FPGS 0.0006
5221 Cytochrome c3, 13 kDa Not Available 0.0006
3152 Cytochrome c'' cycA 0.0006
5220 Split-Soret cytochrome c Ddes_2150 0.0006
3700 Cytochrome c-552 precursor nrfA 0.0006
1760 Aminopeptidase N ANPEP 0.0005
6843 Aminopeptidase N pepN 0.0005
2347 Proto-oncogene serine/threonine-protein kinase Pim-1 PIM1 0.0005
6743 Non-fluorescent flavoprotein luxF 0.0005
6753 Apolipoprotein M APOM 0.0005
2528 Fatty acid metabolism regulator protein fadR 0.0005
6740 Fatty acid metabolism regulator protein fadR 0.0005
6752 Guanylyl cyclase-activating protein 1 GUCA1A 0.0005
394 Calcineurin subunit B isoform 1 PPP3R1 0.0005
6742 Recoverin RCVRN 0.0005
6747 Chalcone/stilbene synthase family protein MT1417 0.0005
6741 Peroxisomal 3,2-trans-enoyl-CoA isomerase PECI 0.0005
6522 Hepatocyte nuclear factor 4-alpha HNF4A 0.0005
6751 Gag polyprotein gag 0.0005
6746 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform PPP3CA 0.0005
6749 Polyprotein Not Available 0.0005
2287 Bifunctional purine biosynthesis protein PURH [Includes: Phosphoribosylaminoimidazolecarboxamide formyltransferase ATIC 0.0005
6211 Tubulin epsilon chain TUBE1 0.0005
6212 Tubulin gamma-1 chain TUBG1 0.0005
6210 Tubulin delta chain TUBD1 0.0005
3127 Nitrite reductase nirS 0.0005
3284 Nitrite reductase nirS 0.0005
5961 Insulin INS 0.0005
6002 Prostaglandin E2 receptor EP4 subtype PTGER4 0.0005
6527 Lymphocyte antigen 96 LY96 0.0005
6755 Poliovirus receptor PVR 0.0005
4131 Prostaglandin E2 receptor, EP3 subtype PTGER3 0.0004
6161 Probable low affinity copper uptake protein 2 SLC31A2 0.0004
406 Prostaglandin E2 receptor, EP2 subtype PTGER2 0.0004
3405 Quinohaemoprotein ethanol dehydrogenase type-1 qheDH 0.0004
6750 ADP-ribosylation factor 6 ARF6 0.0004
4373 Medium-chain-fatty-acid--CoA ligase Not Available 0.0004
6524 Protein tonB tonB 0.0004
2616 Ganglioside GM2 activator GM2A 0.0004
2435 UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase lpxC 0.0004
6613 UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase lpxC 0.0004
2297 Genome polyprotein Not Available 0.0004
2322 Genome polyprotein Not Available 0.0004
2694 Genome polyprotein Not Available 0.0004
2719 Genome polyprotein Not Available 0.0004
2860 Genome polyprotein Not Available 0.0004
2928 Genome polyprotein Not Available 0.0004
3160 Genome polyprotein Not Available 0.0004
3260 Genome polyprotein Not Available 0.0004
4783 Genome polyprotein Not Available 0.0004
5726 Genome polyprotein Not Available 0.0004
5779 Genome polyprotein Not Available 0.0004
5867 Genome polyprotein Not Available 0.0004
6253 Genome polyprotein Not Available 0.0004
6301 Genome polyprotein Not Available 0.0004
6380 Genome polyprotein Not Available 0.0004
6381 Genome polyprotein Not Available 0.0004
6437 Genome polyprotein Not Available 0.0004
6520 Genome polyprotein Not Available 0.0004
6521 Genome polyprotein Not Available 0.0004
6652 Genome polyprotein Not Available 0.0004
6734 Genome polyprotein Not Available 0.0004
6735 Genome polyprotein Not Available 0.0004
6736 Genome polyprotein Not Available 0.0004
6737 Genome polyprotein Not Available 0.0004
6738 Genome polyprotein Not Available 0.0004
6739 Genome polyprotein Not Available 0.0004
6744 Genome polyprotein Not Available 0.0004
6748 Genome polyprotein Not Available 0.0004
6894 Genome polyprotein Not Available 0.0004
6898 Genome polyprotein Not Available 0.0004
6316 ADP-ribosylation factor 1 ARF1 0.0004
864 Gag-Pol polyprotein gag-pol 0.0003
2237 Gag-Pol polyprotein gag-pol 0.0003
2326 Gag-Pol polyprotein gag-pol 0.0003
2451 Gag-Pol polyprotein gag-pol 0.0003
2901 Gag-Pol polyprotein gag-pol 0.0003
3165 Gag-Pol polyprotein gag-pol 0.0003
3722 Gag-Pol polyprotein gag-pol 0.0003
6306 Gag-Pol polyprotein gag-pol 0.0003
6624 Gag-Pol polyprotein gag-pol 0.0003
2240 Cell division protein kinase 2 CDK2 0.0003
2427 Ferrichrome-iron receptor fhuA 0.0003
6264 cAMP-dependent protein kinase inhibitor alpha PKIA 0.0003
6172 ATP-binding cassette sub-family B member 8, mitochondrial ABCB8 0.0003
337 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial NDUFS7 0.0002
803 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial NDUFS2 0.0002
214 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial NDUFS3 0.0002
6168 Solute carrier family 22 member 16 SLC22A16 0.0002
6861 Alcohol dehydrogenase [NADP+] AKR1A1 0.0002
↑